Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60‐day outcomes in the PROTECT pilot study

Dyspnoea is the most common symptom leading to hospitalization for acute heart failure (AHF). Its early and persistent relief is an important goal of therapy, but little is known about its course, determinants, and prognostic significance.

[1]  M. Cheitlin.  B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode , 2010 .

[2]  P. Ponikowski,et al.  Physician-Determined Worsening Heart Failure: A Novel Definition for Early Worsening Heart Failure in Patients Hospitalized for Acute Heart Failure – Association with Signs and Symptoms, Hospitalization Duration, and 60-Day Outcomes , 2009, Cardiology.

[3]  I. Kobrin,et al.  Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome. , 2009, Journal of cardiac failure.

[4]  C. O'connor,et al.  Early worsening heart failure in patients admitted with acute heart failure – a new outcome measure associated with long‐term prognosis? , 2009, Fundamental & clinical pharmacology.

[5]  G. Jondeau,et al.  B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. , 2009, European heart journal.

[6]  K. Swedberg,et al.  Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. , 2009, European heart journal.

[7]  M. Gheorghiade,et al.  Acute heart failure syndromes , 2009, Journal of the American College of Cardiology.

[8]  Paul W Armstrong,et al.  Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. , 2009, Journal of the American College of Cardiology.

[9]  R. Califf,et al.  Changing preferences for survival after hospitalization with advanced heart failure. , 2008, Journal of the American College of Cardiology.

[10]  C. O'connor,et al.  Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). , 2008, Journal of cardiac failure.

[11]  C. O'connor,et al.  The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. , 2008, Journal of cardiac failure.

[12]  J. Cleland,et al.  Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK‐1827452 , 2008, European journal of heart failure.

[13]  George A Mensah,et al.  Heart failure-related hospitalization in the U.S., 1979 to 2004. , 2008, Journal of the American College of Cardiology.

[14]  M. Gheorghiade,et al.  A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. , 2008, European heart journal.

[15]  M. Metra,et al.  Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance , 2008, European journal of heart failure.

[16]  C. O'connor,et al.  Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. , 2007, JAMA.

[17]  B. Massie,et al.  The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. , 2007, Journal of the American College of Cardiology.

[18]  V. Hasselblad,et al.  Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE Trial , 2007, European journal of heart failure.

[19]  John G F Cleland,et al.  Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. , 2007, Journal of cardiac failure.

[20]  H. Dittrich,et al.  The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. , 2007, Journal of cardiac failure.

[21]  Michael Böhm,et al.  Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology , 2007, European journal of heart failure.

[22]  C. Phillips,et al.  Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[23]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[24]  Nancy M Albert,et al.  Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.

[25]  P. Ponikowski,et al.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. , 2006, European heart journal.

[26]  N. Freemantle,et al.  Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE , 2006, European journal of heart failure.

[27]  C. Yancy,et al.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.

[28]  V. Hasselblad,et al.  Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. , 2005, Journal of cardiac failure.

[29]  W John Boscardin,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.

[30]  C. O'connor,et al.  Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. , 2004, Journal of the American College of Cardiology.

[31]  N. Freemantle,et al.  The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta‐regression analysis , 2002, European journal of heart failure.

[32]  C. O'connor,et al.  The prognostic importance of different definitions of worsening renal function in congestive heart failure. , 2002, Journal of cardiac failure.

[33]  James B. Young.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[34]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[35]  M. Cuffe.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. , 2002, JAMA.